Cargando…

The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy

BACKGROUND AND PURPOSE: The derived neutrophil–lymphocyte ratio (dNLR) is a validated prognostic biomarker for cancer survival but has not been extensively studied in locally-advanced oesophageal cancer treated with definitive chemoradiotherapy (dCRT). We aimed to identify the prognostic value of dN...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Samantha, Hurt, Christopher, Grenader, Tal, Mukherjee, Somnath, Bridgewater, John, Crosby, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Scientific Publishers 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648078/
https://www.ncbi.nlm.nih.gov/pubmed/28893415
http://dx.doi.org/10.1016/j.radonc.2017.08.023
_version_ 1783272330065084416
author Cox, Samantha
Hurt, Christopher
Grenader, Tal
Mukherjee, Somnath
Bridgewater, John
Crosby, Thomas
author_facet Cox, Samantha
Hurt, Christopher
Grenader, Tal
Mukherjee, Somnath
Bridgewater, John
Crosby, Thomas
author_sort Cox, Samantha
collection PubMed
description BACKGROUND AND PURPOSE: The derived neutrophil–lymphocyte ratio (dNLR) is a validated prognostic biomarker for cancer survival but has not been extensively studied in locally-advanced oesophageal cancer treated with definitive chemoradiotherapy (dCRT). We aimed to identify the prognostic value of dNLR in patients recruited to the SCOPE1 trial. MATERIALS AND METHODS: 258 patients were randomised to receive dCRT ± cetuximab. Kaplan–Meier’s curves and both univariable and multivariable Cox regression models were calculated for overall survival (OS), progression free survival (PFS), local PFS inside the radiation volume (LPFSi), local PFS outside the radiation volume (LPFSo), and distant PFS (DPFS). RESULTS: An elevated pre-treatment dNLR ≥ 2 was significantly associated with decreased OS in univariable (HR 1.74 [95% CI 1.29–2.35], p < 0.001) and multivariable analyses (HR 1.64 [1.17–2.29], p = 0.004). Median OS was 36 months (95% CI 27.8–42.4) if dNLR < 2 and 18.4 months (95% CI 14.1–24.9) if dNLR ≥ 2. All measures of PFS were also significantly reduced with an elevated dNLR. dNLR was prognostic for OS in cases of squamous cell carcinoma with a non-significant trend for adenocarcinoma/undifferentiated tumours. CONCLUSIONS: An elevated pre-treatment dNLR may be an independent prognostic biomarker for OS and PFS in oesophageal cancer patients treated with definitive CRT. dNLR is a simple, inexpensive and readily available tool for risk-stratification and should be considered for use in future oesophageal cancer clinical trials. The SCOPE1 trial was an International Standard Randomised Controlled Trial [number 47718479].
format Online
Article
Text
id pubmed-5648078
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier Scientific Publishers
record_format MEDLINE/PubMed
spelling pubmed-56480782017-10-25 The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy Cox, Samantha Hurt, Christopher Grenader, Tal Mukherjee, Somnath Bridgewater, John Crosby, Thomas Radiother Oncol Article BACKGROUND AND PURPOSE: The derived neutrophil–lymphocyte ratio (dNLR) is a validated prognostic biomarker for cancer survival but has not been extensively studied in locally-advanced oesophageal cancer treated with definitive chemoradiotherapy (dCRT). We aimed to identify the prognostic value of dNLR in patients recruited to the SCOPE1 trial. MATERIALS AND METHODS: 258 patients were randomised to receive dCRT ± cetuximab. Kaplan–Meier’s curves and both univariable and multivariable Cox regression models were calculated for overall survival (OS), progression free survival (PFS), local PFS inside the radiation volume (LPFSi), local PFS outside the radiation volume (LPFSo), and distant PFS (DPFS). RESULTS: An elevated pre-treatment dNLR ≥ 2 was significantly associated with decreased OS in univariable (HR 1.74 [95% CI 1.29–2.35], p < 0.001) and multivariable analyses (HR 1.64 [1.17–2.29], p = 0.004). Median OS was 36 months (95% CI 27.8–42.4) if dNLR < 2 and 18.4 months (95% CI 14.1–24.9) if dNLR ≥ 2. All measures of PFS were also significantly reduced with an elevated dNLR. dNLR was prognostic for OS in cases of squamous cell carcinoma with a non-significant trend for adenocarcinoma/undifferentiated tumours. CONCLUSIONS: An elevated pre-treatment dNLR may be an independent prognostic biomarker for OS and PFS in oesophageal cancer patients treated with definitive CRT. dNLR is a simple, inexpensive and readily available tool for risk-stratification and should be considered for use in future oesophageal cancer clinical trials. The SCOPE1 trial was an International Standard Randomised Controlled Trial [number 47718479]. Elsevier Scientific Publishers 2017-10 /pmc/articles/PMC5648078/ /pubmed/28893415 http://dx.doi.org/10.1016/j.radonc.2017.08.023 Text en © 2017 The Authors http://creativecommons.org/licenses/by/3.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Cox, Samantha
Hurt, Christopher
Grenader, Tal
Mukherjee, Somnath
Bridgewater, John
Crosby, Thomas
The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
title The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
title_full The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
title_fullStr The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
title_full_unstemmed The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
title_short The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
title_sort prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648078/
https://www.ncbi.nlm.nih.gov/pubmed/28893415
http://dx.doi.org/10.1016/j.radonc.2017.08.023
work_keys_str_mv AT coxsamantha theprognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT hurtchristopher theprognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT grenadertal theprognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT mukherjeesomnath theprognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT bridgewaterjohn theprognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT crosbythomas theprognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT coxsamantha prognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT hurtchristopher prognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT grenadertal prognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT mukherjeesomnath prognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT bridgewaterjohn prognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy
AT crosbythomas prognosticvalueofderivedneutrophiltolymphocyteratioinoesophagealcancertreatedwithdefinitivechemoradiotherapy